

Reactivation of telomerase has been implicated in human tumorigenesis, but the underlying mechanisms remain poorly understood. Here we report the presence of recurrent somatic mutations in the TERT promoter in cancers of the central nervous system (43%), bladder (59%), thyroid (follicular cell-derived, 10%) and skin (melanoma, 29%). In thyroid cancers, the presence of TERT promoter mutations (when occurring together with BRAF mutations) is significantly associated with higher TERT mRNA expression, and in glioblastoma we find a trend for increased telomerase expression in cases harbouring TERT promoter mutations. Both in thyroid cancers and glioblastoma, TERT promoter mutations are significantly associated with older age of the patients. Our results show that TERT promoter mutations are relatively frequent in specific types of human cancers, where they lead to enhanced expression of telomerase. © 2013 Macmillan Publishers Limited. All rights reserved.
| EMTREE drug terms: | B Raf kinasemessenger RNAtelomerasetelomerase reverse transcriptase |
|---|---|
| GEOBASE Subject Index: | agecancerenzymeenzyme activitynervous systemreactivationskintumor |
| EMTREE medical terms: | age distributionarticlebladder cancercancer cell culturecancer geneticscancer patientcentral nervous system tumorcontrolled studygene frequencyglioblastomahumanhuman cellmelanomapromoter regionprotein expressionsomatic mutationthyroid cancerthyroid follicular carcinoma |
| MeSH: | AdolescentAdultAge FactorsAgedAged, 80 and overCell Line, TumorCell Transformation, NeoplasticChildFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedMutation RateNeoplasmsPromoter Regions, GeneticTelomerase |
telomerase reverse transcriptase, 120178-12-3;
TERT protein, human, 2.7.7.49; Telomerase, 2.7.7.49
| Funding sponsor | Funding number | Acronym |
|---|---|---|
| European Regional Development Fund | ||
| SFRH/BD/ 81940/2011,PIC/IC/83037/2007,SFRH/BD/79135/2011 | ||
| Ministry of Science, Technology and Space | ||
| Fundação para a Ciência e a Tecnologia See opportunities | SFRH/BPD/85249/2012 | |
| Fundação para a Ciência e a Tecnologia See opportunities |
We thank to Mrs Mafalda Rocha for the excellent technical support in the sequencing work. This work was partially supported by the Portuguese Science and Technology Foundation (FCT) through BPD (SFRH/BPD/85249/2012 to H.P.), PhD (SFRH/BD/ 81940/2011 to J.V. and SFRH/BD/79135/2011 to A.A.) and BI grants, and the grant through the Program Ciência 2008 (J.L.) and the project (PIC/IC/83037/2007). Further funding was obtained from the project ‘Microenvironment, metabolism and cancer’ partially supported by Programa Operacional Regional do Norte (ON.2—O Novo Norte), under the Quadro de Referência Estratégico Nacional (QREN), and through the Fundo Europeu de Desenvolvimento Regional (FEDER). IPATIMUP is an associate laboratory of the Portuguese Ministry of Science, Technology and Higher Education and is partially supported by the FCT.
Soares, P.; Institute of Molecular Pathology and Immunology, University of Porto (IPATIMUP), Portugal;
© Copyright 2014 Elsevier B.V., All rights reserved.
© MEDLINE® is the source for the MeSH terms of this document.